DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: 8,236,804
|Title:||Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride|
|Abstract:||The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.|
|Inventor(s):||Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE)|
|Assignee:||Merck Patentgesellschaft (Darmstadt, DE)|
1. A method of treating a major depressive disorder, the method comprising: administering to a patient in need thereof a pharmaceutical composition comprising an
effective amount of a compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride anhydrate in crystalline modification IV (Form IV) having at least five characteristic peaks selected from the degrees
two-theta values corresponding to 9.08.+-.0.1, 12.85.+-.0.1, 14.50.+-.0.1, 16.89.+-.0.1, 18.89.+-.0.1, 20.43.+-.0.1, 21.72.+-.0.1, 24.61.+-.0.1, 27.35.+-.0.1 and 28.18.+-.0.1 and one or more conventional auxiliary substances and/or carriers, wherein the
major depressive disorder is treated in the patient.
2. The method of claim 1, wherein the compound has at least five characteristic peaks selected from the degrees two-theta values corresponding to 12.85.+-.0.1, 14.50.+-.0.1, 20.43.+-.0.1, 21.72.+-.0.1, 27.35.+-.0.1 and 28.18.+-.0.1.
3. The method of claim 1, wherein the compound has characteristic peaks at the degrees two-theta values corresponding to 9.08.+-.0.1, 14.50.+-.0.1, 18.89.+-.0.1, 20.43.+-.0.1 and 24.61.+-.0.1.
4. The method of claim 1, wherein, the compound has a solubility in water of about 0.33 .mu.g/mL.
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.